Mohammadhadi Khorrami

Publications

Khorrami, M., Bera, K., Thawani, R., Rajiah, P., Gupta, A., Fu, P., Linden, P., Pennell, N., Jacono, F., Gilkeson, R., Velchetii, V., & Madabhushi, A. (2021). Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. European Journal of Cancer, 148 , 146 - 158.
Khorrami, M., Bera, K., Leo, P., Vaidya, P., Patil, P., Thawani, R., Velu, P., Rajiah, P., Alilou, M., Choi, H., Feldman, M., Gilkeson, R., Linden, P., Fu, P., Pass, H., Velcheti, V., & Madabhushi, A. (2020). Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study. Lung Cancer, 142 , 90-97.
Khorrami, M., Bera, K., Leo, P., Vaidya, P., Patil, P., Thawani, R., Velu, P., Rajiah, P., Alilou, M., Choi, H., & Others, H. (2020). Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study. Lung Cancer, 142 , 90--97.
Khorrami, M., Prasanna, P., Gupta, A., Patil, P., Velu, P., Thawani, R., Corredor-Prada, G., Alilou, M., Bera, K., Fu, P., & Others, P. (2020). Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer. Cancer immunology research, 8 (1), 108.
Vaidya, P., Bera, K., Patil, P., Gupta, A., Jain, P., Alilou, M., Khorrami, M., Velcheti, V., & Madabhushi, A. (2020). Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. Journal for immunotherapy of cancer, 8 (2).
Khorrami, M., Prasanna, P., Gupta, A., Patil, P., Velu, P., Thawani, R., Corredor-Prada, G., Alilou, M., Bera, K., Fu, P., Feldman, M., Velcheti, V., & Madabhushi, A. (2020). Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer. Cancer Immunology Research, 8 (1), 108-119.
Khorrami, M., Jain, P., Bera, K., Alilou, M., Thawani, R., Patil, P., Ahmad, U., Murthy, S., Stephans, K., Fu, P., Velcheti, V., & Madabhushi, A. (2019). Corrigendum to �Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features� [Lung Cancer 135 (September) (2019) 1�9]. Lung Cancer, 136
Khorrami, M., Jain, P., Bera, K., Alilou, M., Thawani, R., Patil, P., Ahmad, U., Murthy, S., Stephans, K., Fu, P., Velcheti, V., & Madabhushi, A. (2019). Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer, 135 , 1-9.
Prasanna, P., Khorrami, M., Gupta, A., Patil, P., Khunger, M., Velu, P., Bera, K., Alilou, M., Velcheti, V., & Madabhushi, A. (2019). Intra and perinodular CT delta radiomic features associated with early response to predict overall survival (OS) in immunotherapy-treated non-small cell lung cancer (NSCLC): A multisite multi-agent study.. Journal of Clinical Oncology, 37 (15_suppl), 2588-2588.
Khorrami, M., Khunger, M., Zagouras, A., Patil, P., Thawani, R., Bera, K., Rajiah, P., Fu, P., Velcheti, V., & Madabhushi, A. (2019). Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma. Radiology: Artificial Intelligence, 1 (2).
Beig, N., Khorrami, M., Alilou, M., Prasanna, P., Braman, N., Orooji, M., Rakshit, S., Bera, K., Rajiah, P., Ginsberg, J., Donatelli, C., Thawani, R., Yang, M., Jacono, F., Tiwari, P., Velcheti, V., Gilkeson, R., Linden, P., & Madabhushi, A. (2019). Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas. Radiology, 290 (3), 783-792.
Khorrami, M., Jain, P., Khunger, M., Ahmad, U., Stephans, K., Murthy, S., Velcheti, V., & Madabhushi, A. (2018). Combination of CT derived radiomic features and lymphovascular invasion status to predict disease recurrence following trimodality therapy in non-small cell lung cancer.. Journal of Clinical Oncology, 36 (15_suppl), e24314-e24314.